{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:30:29Z","timestamp":1793230229351,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s40265-020-01384-y","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T09:02:56Z","timestamp":1599123776000},"page":"1491-1497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Daprodustat: First Approval"],"prefix":"10.1007","volume":"80","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"key":"1384_CR1","doi-asserted-by":"crossref","unstructured":"Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Prim Care. 2008;35(2):329\u201344, vii.","DOI":"10.1016\/j.pop.2008.01.008"},{"issue":"4","key":"1384_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1053\/j.ackd.2019.04.004","volume":"26","author":"NS Sanghani","year":"2019","unstructured":"Sanghani NS, Haase VH. Hypoxia-inducible factor activators in renal anemia: current clinical experience. Adv Chronic Kidney Dis. 2019;26(4):253\u201366.","journal-title":"Adv Chronic Kidney Dis."},{"issue":"1","key":"1384_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1053\/j.ajkd.2015.06.030","volume":"67","author":"M Bonomini","year":"2016","unstructured":"Bonomini M, Del Vecchio L, Sirolli V, et al. New treatment approaches for the anemia of CKD. Am J Kidney Dis. 2016;67(1):133\u201342.","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"1384_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12325-017-0655-z","volume":"35","author":"KA Becker","year":"2018","unstructured":"Becker KA, Jones JJ. An emerging treatment alternative for anemia in chronic kidney disease patients: a review of daprodustat. Adv Ther. 2018;35(1):5\u201311.","journal-title":"Adv Ther."},{"issue":"3","key":"1384_CR5","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1124\/jpet.117.242503","volume":"363","author":"JL Ariazi","year":"2017","unstructured":"Ariazi JL, Duffy KJ, Adams DF, et al. Discovery and preclinical characterization of gsk1278863 (daprodustat), a small molecule hypoxia inducible factor-prolyl hydroxylase inhibitor for anemia. J Pharmacol Exp Ther. 2017;363(3):336\u201347.","journal-title":"J Pharmacol Exp Ther."},{"key":"1384_CR6","unstructured":"GlaxoSmithKline. GSK receives first regulatory approval for Duvroq (daprodustat) in Japan for patients with anaemia due to chronic kidney disease [media release]. 29 June 2020. http:\/\/www.gsk.com."},{"key":"1384_CR7","unstructured":"GlaxoSmithKline. Duvroq (Daprodustat): Japanese prescribing information. 2020. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/340278_39990D4F1024_1_01. Accessed 14 Aug 2020."},{"key":"1384_CR8","unstructured":"GlaxoSmithKline, Kyowa Hakko K. GSK and Kyowa Hakko Kirin sign strategic commercialisation deal in Japan for daprodustat, a potential new oral treatment for anaemia associated with chronic kidney disease [media release]. 22 Nov 2018. https:\/\/www.gsk.com."},{"issue":"6","key":"1384_CR9","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/cpdd.342","volume":"6","author":"S Caltabiano","year":"2017","unstructured":"Caltabiano S, Collins J, Serbest G, et al. A randomized, placebo- and positive-controlled, single-dose, crossover thorough QT\/QTc study assessing the effect of daprodustat on cardiac repolarization in healthy subjects. Clin Pharmacol Drug Dev. 2017;6(6):627\u201340.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1384_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.793","author":"M Yamada","year":"2020","unstructured":"Yamada M, Osamura M, Ogura H, et al. A single-dose, open-label, randomized, two-way crossover study in healthy Japanese participants to evaluate the bioequivalence and the food effect on the pharmacokinetics of daprodustat. Clin Pharmacol Drug Dev. 2020. https:\/\/doi.org\/10.1002\/cpdd.793.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"5","key":"1384_CR11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/ckj\/sfz013","volume":"12","author":"S Caltabiano","year":"2019","unstructured":"Caltabiano S, Cizman B, Burns O, et al. Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure. Clin Kidney J. 2019;12(5):693\u2013701.","journal-title":"Clin Kidney J."},{"issue":"Suppl 1","key":"1384_CR12","first-page":"S92","volume":"107","author":"B Shaddinger","year":"2020","unstructured":"Shaddinger B, Andrews S, Mahar K, et al. Pharmacokinetics of daprodustat and metabolites in subjects with normal and impaired hepatic function. Clin Pharmacol Ther. 2020;107(Suppl 1):S92.","journal-title":"Clin Pharmacol Ther."},{"issue":"2","key":"1384_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/cpdd.83","volume":"3","author":"BM Johnson","year":"2014","unstructured":"Johnson BM, Stier BA, Caltabiano S. Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863. Clin Pharmacol Drug Dev. 2014;3(2):109\u201317.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"2","key":"1384_CR14","doi-asserted-by":"publisher","first-page":"e00327","DOI":"10.1002\/prp2.327","volume":"6","author":"S Caltabiano","year":"2018","unstructured":"Caltabiano S, Mahar KM, Lister K, et al. The drug interaction potential of daprodustat when coadministered with pioglitazone, rosuvastatin, or trimethoprim in healthy subjects. Pharmacol Res Perspect. 2018;6(2):e00327.","journal-title":"Pharmacol Res Perspect."},{"issue":"2","key":"1384_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/1744-9987.12962","volume":"24","author":"Y Tsubakihara","year":"2020","unstructured":"Tsubakihara Y, Akizawa T, Nangaku M, et al. A 24-week anemia correction study of daprodustat in Japanese dialysis patients. Ther Apher Dial. 2020;24(2):108\u201314.","journal-title":"Ther Apher Dial."},{"key":"1384_CR16","doi-asserted-by":"crossref","unstructured":"Akizawa T, Nangaku M, Yonekawa T, et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial [abstract no. SaO036]. Nephrol Dial Transplant. 2019;34 (Suppl 1):a350.","DOI":"10.1093\/ndt\/gfz101.SaO036"},{"issue":"1","key":"1384_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ckj\/sfy014","volume":"12","author":"AM Meadowcroft","year":"2019","unstructured":"Meadowcroft AM, Cizman B, Holdstock L, et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clin Kidney J. 2019;12(1):139\u201348.","journal-title":"Clin Kidney J."},{"issue":"1","key":"1384_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/ckj\/sfy013","volume":"12","author":"L Holdstock","year":"2019","unstructured":"Holdstock L, Cizman B, Meadowcroft AM, et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clin Kidney J. 2019;12(1):129\u201338.","journal-title":"Clin Kidney J."},{"issue":"6","key":"1384_CR19","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1053\/j.ajkd.2015.11.021","volume":"67","author":"RA Brigandi","year":"2016","unstructured":"Brigandi RA, Johnson B, Oei C, et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2A randomized trial. Am J Kidney Dis. 2016;67(6):861\u201371.","journal-title":"Am J Kidney Dis."},{"issue":"4","key":"1384_CR20","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1681\/ASN.2014111139","volume":"27","author":"L Holdstock","year":"2016","unstructured":"Holdstock L, Meadowcroft AM, Maier R, et al. Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J Am Soc Nephrol. 2016;27(4):1234\u201344.","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"1384_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000454818","volume":"45","author":"T Akizawa","year":"2017","unstructured":"Akizawa T, Tsubakihara Y, Nangaku M, et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. Am J Nephrol. 2017;45(2):127\u201335.","journal-title":"Am J Nephrol."},{"issue":"1","key":"1384_CR22","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s12882-019-1547-z","volume":"20","author":"CK Bailey","year":"2019","unstructured":"Bailey CK, Caltabiano S, Cobitz AR, et al. A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis. BMC Nephrol. 2019;20(1):372.","journal-title":"BMC Nephrol."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01384-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-020-01384-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01384-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T07:14:05Z","timestamp":1744701245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-020-01384-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":22,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["1384"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01384-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"3 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"S. Dhillon is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}